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In vitro and ex vivo intracellular delivery methods hold the key for releasing the full potential
of tissue engineering, drug development, and many other applications. In recent years, there
has been significant progress in the design and implementation of intracellular delivery systems
capable of delivery at the same scale as viral transfection and bulk electroporation but offering
fewer adverse outcomes. This review strives to examine a variety of methods for in vitro and
ex vivo intracellular delivery such as flow-through microfluidics, engineered substrates, and
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automated probe-based systems from the perspective of throughput and control. Special attention
is paid to a particularly promising method of electroporation using micro/nanochannel based
porous substrates, which expose small patches of cell membrane to permeabilizing electric field.
Porous substrate electroporation parameters discussed include system design, cells and cargos
used, transfection efficiency and cell viability, and the electric field and its effects on molecular
transport. The review concludes with discussion of potential new innovations which can arise from
specific aspects of porous substrate-based electroporation platforms and high throughput, high
control methods in general.
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This review strives to examine a variety of methods for in vitro and ex vivo intracellular
delivery such as flow-through microfluidics, engineered substrates, and automated probe-based
systems from the perspective of throughput and control. Special attention is paid to a particularly
promising method of electroporation using micro/nanochannel based porous substrates, which
expose small patches of cell membrane to permeabilizing electric field.
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1.

Introduction
In vitro intracellular delivery is an extremely important field of research containing untapped
potential due to the inability, until recently, to reap the benefits of high-throughput and
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highly controllable delivery within the same method. Simply put, intracellular delivery
entails the transport of membrane impermeable molecules across the cell membrane. The
most prominent form of intracellular delivery is gene delivery, but the molecules are not
limited to nucleic acids and can consist of proteins, drugs, or any other impermeable
molecule. Although in vivo intracellular delivery is a promising field in its own right, in
vitro intracellular delivery’s potential lies in the simplicity and control afforded by culture
in an artificial environment. In vitro intracellular delivery avoids the complex problems that
occur in vivo such as localization within a particular tissue, avoidance of biological filtration
systems like the blood brain barrier, liver, and kidneys, delivery without generation of a
severe immune response, and complex interactions resulting from the presence of multiple
cell types. Additionally, in vitro intracellular delivery allows environmental modification in
the form of substrate stiffness and culture media to encourage stem cell differentiation[1] and
somatic cell reprogramming and transdifferentiation[2–5].

Author Manuscript
Author Manuscript

In vitro intracellular delivery has medical, industrial, and analytical applications. Particularly
interesting medical applications are adoptive immunotherapy and tissue engineering.
Adoptive immunotherapy includes chimeric antigen receptor T (CAR-T) cell therapy, in
which T cells are reprogrammed through in vitro gene delivery to target cancer cells
before injection into a patient’s bloodstream[6, 7]. Tissue engineering relies on in vitro
gene delivery to reprogram a patient’s somatic cells such as fibroblasts or adipocytes into
induced pluripotent stem cells (iPSCs), which can differentiate into any cells present within
the adult body[8, 9]. In vitro intracellular delivery has applications in industry such as
increasing biomolecular production through the generation of monoclonal cell lines[10–13],
or expediting analysis of the pharmacological effects a particular drug has on primary
cells[14]. Furthermore, in vitro intracellular delivery of fluorophores and molecular beacons
allows biointerrogation of cell types to better understand biomolecular mechanisms.

Author Manuscript

Despite the numerous opportunities provided by in vitro intracellular delivery, significant
obstacles exist for a delivery system to be capable of fulfilling all these applications. The
primary obstacle is delivering impermeable molecules across the cell membrane intact,
a nontrivial task which requires physical disruption of the membrane or endocytosis
followed by endosomal escape prior to lysosomal degradation. The process is further
complicated because maintaining cell viability after delivery is crucial, so any disruption
in the membrane must be temporary, and since many molecules for intracellular delivery
are cytotoxic, the delivered quantity must be well controlled. Moreover, if DNA is being
delivered, the delivery method must contain a mechanism for transporting the DNA through
the cytoplasm and nuclear membrane to enable transcription within the nucleus. Finally,
many of the applications require overcoming all of these obstacles quickly and consistently
for populations of millions of cells.
One of the primary challenges of reviewing in vitro and ex vivo intracellular delivery
methods is determining a classification system that encompasses the diverse spectrum of
methods. Classification is nontrivial as it frames the subject and guides the conclusions
drawn from it. Until now, intracellular delivery methods have been limited to classification
based on the mechanism they use to bypass the cell membrane such as viral, chemical,
and physical. For in vitro and ex vivo intracellular delivery methods, a new framework
Small. Author manuscript; available in PMC 2022 January 05.
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is needed for two reasons. First, a framework is needed to place an emphasis on system
feasibility rather than the underlying vector-based or membrane disruption mechanisms
themselves. In vitro and ex vivo intracellular delivery is a highly valuable field with
no industry standard capable of fulfilling the numerous potential applications. Therefore,
all prospective systems should be analyzed within the context of fulfilling these unmet
needs. Second, a framework is needed to emphasize that the result of various delivery
methods depends more on the scale and application of the mechanism than the mechanism
itself. For example, bulk electroporation, probe-based electroporation, and flow-through
microfluidic electroporation, despite all using electroporation as a delivery mechanism, have
outcomes more in common with bulk sonoporation, single-cell injection, and microfluidic
cell squeezing, respectively, than they do with each other. To satisfy these needs, this
review proposes a new throughput and control classification framework for in vitro and
ex vivo intracellular delivery methods. The classification system described here is not
intended to replace the traditional method-based classification, but rather as a supplement to
provide further insight into the field of in vitro and ex vivo intracellular delivery. Following
discussion of this framework, porous substrate electroporation, one of the intracellular
delivery methods with the greatest potential for industry-wide adoption, is further explored
by dissecting commonalities between existing systems. Finally, an outlook of the field of in
vitro and ex vivo intracellular delivery methods is provided.

Author Manuscript
2.

Throughput and Control
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The many opportunities and challenges of in vitro and ex vivo intracellular delivery have
produced significant research interest and resulted in the proliferation of numerous methods
for intracellular delivery[15, 16]. However, these methods predominantly fall into one of two
categories: high throughput methods able to induce intracellular delivery into millions of
cells within a short time by relying on broad, stochastic processes; and extremely precise,
high control methods which are able to provide high uniformity, viability, and dosage
control, yet their complexity often requires them to be performed at the single-cell scale.
Throughput is a spectrum with no defined number separating low throughput from high
throughput and each category spans multiple orders of magnitude. However, in general we
use the term low throughput to refer to methods capable of delivering to individual cells up
to hundreds of cells within a few hours; we use high throughput to refer to methods that
can be scaled to deliver to hundreds of thousands or more cells within the same timeframe.
For an in vitro intracellular delivery platform to fulfil the diverse and difficult applications
envisioned, both high throughput and high levels of control are essential. As a result, we
have classified all existing in vitro and ex vivo intracellular delivery methods into one
of three categories: high throughput, low control methods; low throughput, high control
methods; and high throughput, high control methods (Figure 1).

Author Manuscript

2.1

High Throughput, Low Control Methods
High throughput, low control intracellular delivery methods were the first to be used to
transfect a large number of cells but have limited mechanisms for control and thus result
in highly stochastic delivery. High throughput, low control intracellular delivery methods
consist of vector mediated delivery such as viral and chemical gene delivery, and bulk
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physical processes like bulk electroporation and bulk sonoporation. Although they can
be used for in vitro intracellular delivery, vector mediated delivery methods are uniquely
suited to in vivo delivery because they can be administered through ingestion, injection,
or absorption through the skin[15, 17, 18]. In contrast, they are poor methods for in vitro
intracellular delivery because while vector concentration can be controlled, delivery is
determined by diffusion and endocytosis, meaning there is no way of precisely controlling
the number of vectors administered to each cell. Likewise, bulk physical processes are ill
suited for in vitro intracellular delivery because they exhibit non-uniform delivery across
populations based on the distribution of cells and physical set-up of the device.

Author Manuscript

Viruses naturally contain highly efficient mechanisms that allow them to bypass the
cell membrane and deliver their genetic information for replication, making modified
viral vectors a natural candidate for intracellular gene delivery. Viral vectors have been
engineered from many different types of viruses, especially adenoviruses, adeno-associated
viruses, herpes simplex viruses, lentiviruses, and retroviruses[19–21]. Viral vectors are
engineered to have their genetic code responsible for viral replication replaced with
the desired genes for delivery, requiring replication to occur in genetically engineered
bacteria or mammalian cells[22, 23]. Utilizing this intrinsic mechanism means the sizes
of the delivered genes are limited by an upper threshold defined by the virus type, and
molecules other than nucleic acids, such as proteins, cannot be delivered virally[21, 24].
More significantly, implementation of viral vectors is concerning due to evidence of
viruses spontaneously regaining their ability to replicate, and oncogenesis through off-target
effects[21].

Author Manuscript
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Chemical vectors were created to utilize the advantages provided by vector based
intracellular delivery while negating the risks associated with viral vectors. Chemical
vectors are particles consisting of nucleic acids electrostatically complexed to inorganic
nanoparticles, or cationic lipids (lipoplexes) and polymers (polyplexes)[25]. Lipoplexes and
polyplexes allow the nucleic acids to enter the cell through endocytosis, which is otherwise
prevented by the negative charge present on the nucleic acids. Following endosomal
internalization, chemical vectors have specially designed coatings to induce endosomal
rupture prior to lysosomal maturation, thereby preventing degradation of the nucleic
acids[26]. Magnetofection is a chemical vector method that also relies on the application
of bulk physical stimuli in the form of a magnetic field. During magnetofection, a polyplex
with associated magnetic nanoparticles is guided to targeted cells via magnetic fields[27].
Despite these innovations, chemical vectors are still unable to match the delivery efficiency
of viral vectors and bulk physical methods[25, 28]. This is particularly apparent in hard-totransfect cells such as stem, progenitor, and primary cells[29]. Increasing concentrations of
chemical vectors high enough to counteract their low efficiency often results in cytotoxicity.
In addition to vector-based methods, high throughput, low control in vitro intracellular
delivery is possible using physical stimuli applied to large populations of cells
simultaneously. These bulk physical methods include bulk electroporation, bulk
photoporation, and bulk sonoporation. Bulk Electroporation (BEP) is the most widely used
bulk physical method and refers to an electroporation method where a high voltage is
applied to a dielectric chamber which can contain thousands to millions of cells[30]. The
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applied voltage produces a transmembrane potential (TMP) that causes a rearrangement of
the membrane resulting in pore formation, allowing for intracellular cargo translocation by
diffusion for small molecules or endocytosis for larger molecules[31]. When the voltage is
removed, the cell membranes self-repair, closing the pores. Electroporation pulses can be
adjusted to control the extent of permeabilization of the cell membrane through amplitude
and pulse duration. The main drawback of BEP is the electric field is known to be
nonuniform both from the large distance between the electrodes[32] and from distortion
of the electric field due to the proximity of cells[33, 34]. This nonuniform electric field
affects the TMP generated on the cells in suspension and thus results in some cells
being irreversibly permeabilized while others have an insufficient TMP for intracellular
delivery to occur. When certain combinations of pulse duration and electric field strength
are applied, significant Joule heating of an electrolyte solution can occur[35]. Since bulk
electroporation applies an electric field to the entire solution surrounding the cells and
some regions of the solution are exposed to more intense electric fields, it is possible that
Joule heating of cells is more significant in bulk electroporation than other more localized
forms of electroporation. Another form of intracellular delivery, bulk photoporation uses a
laser focused onto a cluster of cells to irradiate and transiently permeabilize cells. Light
induced intracellular delivery has been referred to as optoporation[16], optoinjection[36],
laserfection[37], and optical transfection[38], among others. In this review we refer to
any form of light induced membrane permeabilization as photoporation for simplicity.
The mechanism of bulk photoporation typically involves a secondary interaction such as
substrate induced pressure fluctuation[39] or substrate mediated thermal effects [40]. Bulk
photoporation is limited in scale when compared to BEP. Bulk photoporation has lower
throughput than electroporation, coupling this with high cell lysis[39, 41] led to photoporation
studies more focused on the single cell level. Lastly, sonoporation refers to the use of
ultrasound acoustic waves to produce membrane poration through pressure fluctuation
induced stresses[42], stable microbubble cavitation, or inertial microbubble cavitation[43–45].

Author Manuscript
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2.2

Low Throughput, High Control Methods

Author Manuscript

Low throughput, high control in vitro and ex vivo intracellular delivery methods are an
alternative to the lack of control, predictability and efficiency of high throughput, low
control delivery methods. Low throughput, high control methods fulfill the need for precise
interrogation of individual cells to discern underlying pathways and mechanisms. These
methods also provide means of performing difficult transfections on highly valuable cells
such as primary cells. Notably, since these methods employ an enclosed volume and can
apply bidirectional forces to the cell through modulation of pressure or voltage, they
require much lower quantities of expensive reagents, and can be used for intracellular
extraction as well as delivery. For low throughput, high control methods, there are two
main approaches of introducing cargo into the cell: membrane penetration and membrane
poration. Methods of membrane penetration include micro-/nano-injection and ballistic
cargo delivery. Membrane poration methods include single cell electroporation, single
cell photoporation, and single cell sonoporation. These methods are highly focused
techniques which allow single cell manipulation and interrogation with exceedingly sensitive
equipment. As a result, they are time consuming and require a highly trained technician,
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which leaves a desire for higher throughput methods. In this section, methods of membrane
penetration and membrane poration will be further discussed.

Author Manuscript

The main form of membrane penetration intracellular delivery is micro-/nano-injection.
Microinjection was the first form of intracellular injection dating back to 1911[46]. With
the evolution of technology and fabrication techniques, microinjection has evolved into
nano-injection using tips on the order of ~100 nm[47, 48]. Micro-/nano-injection provides
direct intracellular delivery through penetration of the cell membrane to deliver precise
amounts of cargo to the cytosol or nucleus[49, 50]. Recent advancements in this area include
electrophoretic injection control[47] and fluid force microscopy[51]. An additional method
of low throughput, high control membrane penetration is ballistic cargo delivery. Ballistic
cargo delivery entails coating cargo in heavy metal particles and propelling them towards
cells with enough momentum to penetrate the membrane[16, 52]. Ballistic cargo delivery has
shown the ability to introduce large cargo but lacks control and consistency when compared
to other methods of high control delivery.

Author Manuscript

An alternative to membrane penetration, single cell membrane poration can be induced by
highly targeted electric fields, high intensity light, or sound waves. For electric fields, single
cell electroporation (SCE) uses BEP principles scaled down to the single cell level. This
can be categorized as micro/nano electroporation, depending on the scale. The focused
target of the electric field decreases the necessary voltage, reduces joule heating, and
ultimately increases cell viability and transfection efficiency[30, 53, 54]. The narrowed focus
also leads to more detailed insight into the physical and electrical characteristics of the
cell[16, 55]. Through careful variation of the electric pulse parameters (amplitude, duration,
frequency) and the electrophoretic solution, the electroporation parameters can be optimized
based on cell type to facilitate high transfection efficiencies[16, 56]. Notable methods of
singe cell electroporation are nano-fountain probe electroporation (NFP-E) and nanochannel
electroporation. NFP-E uses a conductive atomic force microscopy probe which has a
microfluidic channel. The probe approaches the cell and applies a targeted electric field
to induce poration before delivering the cargo through the microfluidic channel[13, 57, 58].
Nanochannel electroporation contains two microchannels connected by a nanochannel. One
microchannel contains the cell and the other contains the cargo to be delivered. The cell is
electroporated and the cargo is driven into the cytosol by electrophoretic forces[59–61]. SCE
offers a highly controlled method of intracellular delivery without the risks associated with
BEP. This has made it a widely used technique and serves as the basis for many of the
high throughput, high control systems. Photoporation is similar to SCE in that membrane
poration is induced by targeted high intensity light focused on single cells. Photoporation
has been shown to deliver a variety of cargo including plasmid DNA, mRNA, siRNA,
peptide, and proteins among other molecules[16, 62]. Lastly, similarly to the methods used for
bulk sonoporation, acoustics have been used for single cell sonoporation[63, 64].

Author Manuscript

2.3

High Throughput, High Control Methods
Following development of the low throughput, high control methods, researchers began
looking for ways to adapt these methods to meet the high throughput requirements of
many in vitro intracellular applications. The resulting high throughput, high control methods
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can be broadly classified into three main categories: automated probe-based systems, flowthrough microfluidic systems, and complex substrates (Figure 2). Since micromanipulator
based intracellular delivery methods already rely on electronics for their motion, automated
probe-based systems are the natural solution to their low throughput caused by high
precision and lack of parallel delivery capability. These systems have the potential to
provide the highest control of any high throughput, high control methods, but unfortunately,
are still unable to scale as well as other high throughput methods. The second main
category, flow-through microfluidic systems, encompass both microfluidic squeezing and
microfluidic electroporation methods. These methods have the capability to be extremely
high throughput by increasing flow rate and the number of microfluidic channels, yet
also require cellular suspension, which is undesirable for sensitive, adherent cells, and
exhibit less control over their delivery mechanisms than automated probe-based methods
or complex substrate methods. Complex substrate methods encompass a diverse spectrum
of devices primarily grouped into nanostructure-based and electroporation-based methods,
with some overlap between the two. Complex substrates may not provide the level of
control of automated probe-based methods or the throughput of flow-through microfluidic
systems, but they are simpler to develop than automated probe-based systems and provide a
desirable adherent environment with more control than flow-through microfluidic systems.
There are a few systems that fall outside of these three categories, notably nanostructure
stamping which involves apically penetrating a population of cells using an array of
nanostructures[65–68]. This method is not widely used and suffers from many of the same
drawbacks discussed with nanostructure substrates, while incurring additional complexity by
requiring the nanostructures to be applied rather than allowing spontaneous penetration.

Author Manuscript
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2.3.1 Automated Probe-Based Methods—Automated probe-based methods have
been developed for microinjection and single-cell electroporation (SCE) systems. These
automated systems use the fundamentals associated with their single-cell variant but with the
addition of platform control, cell detection, and automated cargo delivery. Automated probebased systems are the most controlled delivery process of any high throughput systems
due to their requirement that they treat each cell individually. However, these methods are
also perhaps the most expensive, complex, and difficult to scale of any high throughput
system. Evolution of automated probes into higher throughput systems will require faster
injection, faster cell recognition, and faster cell positioning[69]. These methods remain
promising particularly for analytical applications where subcellular processes are studied,
but their cost and poor scalability remain significant obstacles to widespread medical and
industrial adoption. Targeted delivery, i.e. the delivery of cargos to subcellular regions
and particularly the nucleus, has not been widely demonstrated in intracellular delivery
methods other than probe-based methods. Automated microinjection and SCE both use
micromanipulator platforms coupled with cell detection methods to locate and precisely
transfect cells, therefore we will first discuss cell detection and platform control before
discussing each cellular contact method individually.
Automated probes utilize image processing algorithms[69] to precisely control the movement
of a micro-/nano- positioning platform. Despite the widespread accessibility of cell
detection image processing algorithms[70, 71], image processing for an in vitro intracellular
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delivery system remains nontrivial due to cell transparency, clustering and overlapping in
confluent populations, and varying morphologies[72, 73]. These challenges initially led to
the development of automated microinjection systems focused on using zebra fish embryo
due to their large size and defining features[74, 75]. Additionally, many image processing
algorithms rely on fluorophores to identify cells, but these fluorophores may be undesirable
in some applications due to their toxicity or potential for mutagenesis[76].

Author Manuscript

Automated microinjection (Figure 2A) delivers the cargo through injection as discussed in
the previous section. To automate delivery, these systems require force measurements from
the needle to determine when penetration has occurred[77]. Numerous methods of microforce sensors were developed for the needle such as piezoelectric sensors[78], piezoresistive
sensors[79], and MEMS capacitive force sensors[80, 81]. In addition to the automated zebra
fish embryo microinjection devices, systems have been developed for smaller and harder to
transfect cells[69, 82–87]. In contrast, automated single-cell electroporation systems (Figure
2B) do not penetrate the cell membrane but rather closely approach or slightly contact
the membrane. Therefore, a method of membrane detection is necessary to automate the
process. Electroporation relies on circuitry to induce poration; this same circuitry can be
used to detect the cell membrane[58, 88, 89]. As the conductive probe approaches and seals
against the cell membrane, a significant decrease in current can be detected. This method
has been used to automate SCE devices via capillary probe electroporation[90], and nanofountain probe electroporation[13, 57, 91].
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2.3.2 Flow-Through Microfluidic Methods—Flow-through microfluidic devices
offer throughput comparable to bulk methods while retaining localized cellular control.
This category of devices can be divided into two categories: electroporation and
mechanoporation. Flow-through microfluidic electroporation uses microfluidic channels
to flow cells like a fluid and rapidly position them in close proximity to electrodes for
a localized membrane permeabilization. Mechanoporation refers to mechanically induced
membrane permeabilization through shear forces created by physical interaction such as
passage constriction (cell squeezing) or fluid crossflows (hydroporation). Further, methods
using both these techniques in series have been developed for high throughput nuclear DNA
delivery[92]. Microfluidic devices can be fabricated using standard lithographic techniques
and provide the highest throughput method of any of the high throughput, high control
methods, and are not expensive to produce. However, microfluidic systems rely on cell
to cell consistency and this can result in inconsistent delivery or clogging. Furthermore,
flow-through devices rely on suspended cells making it a more stressful process for adherent
cells.

Author Manuscript

The method of flow-through microfluidic electroporation (Figure 2C) uses embedded
electrodes within microfluidic channels to permeabilize the cell membranes as they flow
past the electrodes. The cells are suspended in a solution which contains the cargo to
be delivered, and upon electroporation intracellular delivery takes place. Various methods
and channel geometries have been explored for increased throughput and viability[93–97].
The microscale channels allow for narrow electrode gaps resulting in lower voltage
requirements[94] and the microfluidic flow further helps to reduce negative effects
such as joule heating and gas bubble evolution[98]. Notable studies include single cell
Small. Author manuscript; available in PMC 2022 January 05.

Brooks et al.

Page 10

Author Manuscript

impedence measurements for a flow through device[99] demonstrating single cell control.
Furthermore, constant voltage flow-through electropartion systems have been designed with
oil droplets[100] and varying channel width[101] which show the potential simplicity of flowthrough electroporation devices. Some drawbacks of microfluidic electroporation are that
it can require complex electrode geometry which are difficult to fabricate and additionally
optimizing the electrical parameters for efficient transfection and high viability is a time
consuming process.

Author Manuscript
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The other main category of flow-through microfluidics, mechanoporation (Figure 2D),
encompasses microfluidic cell squeezing and hydroporation. Cell squeezing devices are
microfluidic devices that transfer molecules into cells by permeabilizing the cell membrane
though deformation. In these devices, a solution of cells and cargo is flowed into
microchannels which constrict the cells, typically the channel width is ~40–50% of the
cell diameter. As a result, cells are squeezed as they flow into the constriction, and the
cell membrane is temporarily permeabilized. After delivery, the cells are often left at room
temperature for a few minutes to permit resealing. Cell speed, channel dimensions, and
the number of constrictions are parameters that influence the delivery. In these devices, the
transfection efficiency increases by increasing the flow rate and decreasing the gap size,
while the cell viability decreases. This method has a high throughput transfection result can
in some cases they can deliver into 1 million cells per second[102], and macromolecules
with a variety of ranges delivered into cells[103]. Although targeted nuclear delivery has
been previously limited to probe-based methods, Ding et al. developed a combined cell
squeezing and electric-field-driven transport integrated in a single microfluidic device
capable of accelerated nuclear delivery of plasmid DNA, and they reported higher delivery
efficiency with low voltages compared to microfluidic electroporation alone[92]. One of the
drawbacks of squeezing devices is that they are not able to perform for many experiments
due to their small sizes, and the channels will be clogged and reduce the efficiency of the
devices. Hydroporation is functionally similar to microfluidic cell squeezing, but instead of
constrictions, a perpendicular fluid cross flow induces cell poration to allow for intracellular
delivery. This method has the highest delivery efficiency and cell viability of all microfluidic
techniques[104, 105]. Delivery efficiency in hydroporators is a balance between delivery and
viability that can be controlled through the Reynolds number of the fluid flow. Notably,
nanomaterials with a variety of sizes ranging up to 2000 kDa have been delivered using
a platform based on spiral vortex and vortex breakdown due to the flow at the cross and
T-junctions[104].

Author Manuscript

2.3.3 Engineered Substrate Methods—Engineered substrates is a term we have
chosen to encompass all methods where substrates containing micro- or nanoscale features
are used for intracellular delivery[106–108]. These substrates are often used to apply localized
electroporation to randomly deposited cells, but some can be used with other physical
stimuli such as photoporation[109] and possibly sonoporation. These methods include
one dimensional nanostructures, patterned electrodes, and substrates containing microor nanopores.[106–108] Although these methods can require sophisticated manufacturing
processes, many of these processes have already been developed within the microelectronics
and microfiltration industries for efficient production at an industrial scale. As such, these
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substrates are readily scalable and can be widened and stacked to process numerous cells
simultaneously, and are inexpensive to produce. Like probe-based methods, these systems
are primarily suited for in situ intracellular delivery of adherent cells but can be utilized
for suspended cell delivery using cell trapping or centrifugation. These systems can also be
placed in series with other microfluidic processes such as cell sorting. Although engineered
substrates do not provide as much control as automated probe-based methods or as high of
throughput as flow-through microfluidic methods, they offer a compromise of many of the
advantages of in situ adherent delivery while remaining highly scalable. Due to this balance
of throughput and control, we consider engineered substrate methods the most promising
subset of all high throughput, high control methods.
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Nanostructure substrates (Figure 2E) are a group of methods utilizing one-dimensional
structures such as nanoneedles[107, 110], nanowires[111–117], nanotubes[118, 119], and
nanostraws[120–123] with diameters small enough that when cells are adhered to them
they either induce spontaneous penetration, alter membrane permeabilization, or elicit
endocytosis for molecular delivery. There is an ongoing debate as to which of these
mechanisms or combination of mechanisms is primarily responsible for delivery using
nanostructures[124]. Following penetration, the cell membrane seals around the base
of the structure. Intracellular delivery can occur through molecules adsorbed to the
surface, as is the case with solid nanoneedles, solid nanopillars, solid nanowires, and
nanotubes sealed at one end; or by permanent intracellular access provided by hollow
nanostructures such as hollow nanoneedles, nanotubes, and nanowires. Both approaches
have disadvantages: solid and sealed nanostructures do not permit molecular extraction
and only allow a single delivery without detaching and reattaching the cells, whereas
hollow nanostructures cause continuous delivery of extracellular molecules and continuous
leakage of intracellular molecules as long as the cell remains adhered. Nanostructures may
be uniformly or stochastically spaced depending on the fabrication process. Furthermore,
nanostructures are fragile and require more complex manufacturing than some other
engineered substrates. Conversely, nanostructures are the only engineered substrates that
do not require electroporation or other physical stimuli for delivery, and thus do not require
any electronics.
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To resolve adsorption and continued leakage when using nanostructures, some researchers
have combined nanostructures with electroporation (Figure 2F)[125–134]. Nanostructures that
are slightly too wide to cause spontaneous penetration are coated with a conductive material
along the outside of the structure. Once cells are adhered to the substrate, electroporation
can be used similarly to a valve to open the membrane at the end of each nanostructure.
This allows for prolonged intracellular access lasting days or weeks, during which molecules
can be added or extracted as desired. Electroporation increases the delivery efficiency
of nanostructures and the tight seal at the cell membrane-substrate interface reduces the
voltage necessary for electroporation by elevating the electric field applied to the interface.
Electroporation in conjunction with nanostructures, including nanostraws and nanotubes,
may form a tighter seal compared to porous substrates due to the high aspect ratio of the
1D structures[118, 133]. In addition to intracellular delivery, the conductive nanostructures can
be used to record intracellular electrical measurements, although this requires nanostructures
for each cell to be connected to a different electrode[132]. Nanostructure electroporation
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has many of the same disadvantages as nanostructures, namely fragility and manufacturing,
the latter of which is even more difficult with the added conductive layers. Furthermore,
electroporation requires additional electronics attached to the substrates.

Author Manuscript

Patterned electrode substrates (Figure 2G) are substrates similar to printed circuit boards,
containing thin conductive paths exposed to cells. These electrodes can be made in
many different patterns, including interdigited[135–141], ring-dot[142], and clover[143], among
others[144–150]. These electrodes should be as closely spaced as possible to localize
the electric field to individual cells and avoid the harmful effects associated with bulk
electroporation. One advantage of patterned electrode substrates is they can be used to
understand electroporation parameters by modifying the electrode geometry, as is the case
with clover electrodes and electric field strength[143]. Moreover, the proximity of the
electrodes and high electric field strength between them induces corrosion and requires
substrate replacement or replating for repeated use. Since patterned electrode substrates
do not have a cargo reservoir separate from the cell culture chamber like other substrate
methods, higher quantities of expensive reagents are necessary.
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The last category of high throughput, high control systems, porous substrate systems (Figure
2H) are substrates containing numerous micro- and nanopores on which cells are seeded
and electroporated. Porous substrates can consist of commercially available membranes with
random pore distribution[151–159], or uniform arrays of pores on silicon chips[160–170]. Like
nanostructures, cells seal around the pores which limits the electric field exposure to discrete
regions of each cell. Nanostructures may generate tighter seals at the membrane-substrate
interface, but it has been shown that prior coating of substrates with extracellular matrix
proteins can significantly enhance this seal in porous substrate-based methods to achieve
high efficiency electroporation[171]. Although sharing many similarities to other engineered
substrate methods, porous substrates benefit from increased robustness due to their lack of
fragile nanostructures and corrosion-prone electrodes. Additionally, porous substrates are
easier to produce because they require less material to be removed than nanostructures and
do not require conductive layers like patterned electrode substrates.

3.

High Throughput, Highly Controllable Porous Substrate Electroporation

Author Manuscript

Porous substrate methods are uniquely capable of achieving widespread adoption and
making many of the aspirations of in vitro and ex vivo intracellular delivery a reality.
Within high throughput, high control methods, it is our opinion that engineered substrates
have the best balance of throughput and control due to their capacity for highly scalable in
situ delivery. More specifically, porous substrates have been shown to perform similarly to
more complicated alternative engineered substrates[119, 126, 141, 171]. Furthermore, evidence
gathered using porous substrates is substantial enough to show promise amongst a variety
of cell types using many different cargos, but there are significant opportunities for future
research to better understand the fundamental processes involved, further optimize existing
systems, and to use these systems in more complex biological applications. The following
section serves as a review of the recent research efforts in the design and application of
porous substrate electroporation systems in terms of design features, cell culture, cargo
limitations, and choices of electroporation parameters (Figure 3). While porous substrates
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can be utilized with other methods of membrane permeabilization such as photoporation
and these methods are certainly worthy of further investigation, this section is devoted
specifically to porous substrate electroporation systems because they have been much more
widely utilized.

[109]

3.1

Theory of Electrical Potential and Molecular Transport
It is generally accepted that the application of an electric field leads to the formation of
hydrophilic pores from hydrophobic pores on the cell membrane (Figure 3D), which allows
for the transport of molecules across it[172, 173]. The formation and evolution of these
transient hydrophilic pores are modeled using the Smoluchowski equation:
∂n rp, t
∂E σe, V m
∂2 n Dp ∂
= Dp 2 +
n
∂t
∂rp
∂rp kT ∂rp

1)

Author Manuscript

where n is the size density of electropores per unit membrane area, Dp is the pore diffusion
coefficient in the pore radius space rp, kT is the thermal energy, and E is the energy
difference between cell membranes with and without hydrophilic electropores. The energy E
is a function of the effective membrane tension σe and the transmembrane potential (TMP)
V m, which is the potential difference developed across the cell membrane on the application

of the electric field. The Smoluchowski equation along with appropriate boundary
conditions has been frequently used in combination with electric field and molecular
transport models to estimate and optimize bulk electroporation based delivery[174–178].
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More recently, this equation was incorporated in a multiphysics model to predict the
molecular transport in porous substrate based localized electroporation platforms [152]. In
this model it was assumed that the electric field is localized at the interface of the nanopores
and the cell membrane, which was indirectly observed during delivery experiments in other
studies[59, 179]. This made it possible to use an equivalent circuit approximation to estimate
the localized electric field (Figure 3B). The physical components of the system such as cell
membrane, nanopore resistance, buffer and contact impedance were assumed to be passive
electrical circuit components and the following charge conservation equation was solved:
∇ . κ n ∇V +

∂
∇ . ϵ ∇V = 0
∂t

2)

Author Manuscript

where V is the potential drop across any component, κ is the conductivity that depends on
the density of electropores n in case of the cell membrane and ϵ is the permittivity. The
molecular transport was assumed to be diffusive and electrophoretic and solved using the
Nernst-Planck equation:
Dze
∂c
= ∇ . D ∇c +
∇ . c ∇V
∂t
kT
where, c is the concentration of the molecular specie moving across the nanopore, D is the
diffusion coefficient, z is the charge of the specie and e is the elementary charge constant.
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The electrophoretic nature of the transport was also verified by researchers using localized
electroporation based platforms[151, 180].
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This multiphysics model allowed for the optimization of physical parameters involved in
localized electroporation such as pore density, size, and electroporation pulse profiles.
Additionally, a few key conclusions were drawn from the model predictions that were
supported by the experimental data. First, it was inferred that an optimal voltage
exists for efficient electroporation and delivery of large molecules. Voltages lower than
optimal do not lead to the formation of sufficient pores and very high voltages lead
to the formation of excessive small pores that cannot expand enough to permit the
entry of large molecules. This prediction corroborated well with experimental results
reported in the study and data reported in literature using similarly designed localized
electroporation platforms[151, 181]. Second, the model predicted that the cell membrane
tension plays a key role in efficient delivery during electroporation and higher membrane
tension allows for a greater amount of cargo to be delivered with better uniformity.
Osmolarity induced membrane tension was used to validate this conclusion. Moreover, this
conclusion is not surprising considering mechanical perturbation methods, such as physical
squeezing and hydrodynamic deformation that increase the membrane tension and eventual
permeabilization, have emerged as efficient methods of intracellular delivery[15, 16]. Overall,
the multiphysics model provides a useful framework that can qualitatively guide the design
of localized electroporation platforms and optimization of experimental conditions.

Author Manuscript

Although the continuum scale models provide valuable insights into the mechanisms of
localized electroporation mediated delivery, they use several assumptions regarding the
electropore dynamics and molecular transport that are reflected in the model parameters.
These parameters are difficult to quantify accurately, because of which the model estimates
have uncertainties. To obtain robust quantitative predictions the uncertainties need to be
quantified using systematically designed experimental validations. Additional information
that complement the continuum models can be obtained from molecular dynamics
simulations capturing the interactions of the delivery cargo and the lipid pores[182, 183]. Such
multiscale approaches may also provide explanations for experimental observations unique
to localized electroporation, for example, the uniform distribution of molecular cargo in the
cytoplasm suggesting direct electrophoretic entry bypassing the endocytic pathway[59].
3.2

System Design

Author Manuscript

There are many parameters related to system design that affect the performance of
porous substrate systems (Table 1) including electrode materials and whether cell trapping
mechanisms are used, as well as pore diameter, length, density, and whether the pores
are uniformly distributed. The two electrodes can consist of the same material or different
materials. These electrodes tend to be made of noble metals such as gold, silver, or platinum
to resist electrolytic corrosion, or glass with a thin conductive layer to allow viewing
under a microscope while retaining fluids and providing structural support. Multiple cell
trapping methods have been used with porous substrates to increase the likelihood of cell
positioning over pores, and to ensure tight contact between the cell and pore opening
(Figure 3A). These cell trapping methods include nanostructures around the pores[161],
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vacuum[156, 160, 163, 167, 168], dielectrophoresis[165], and magnetic tweezers[163] but must
be carefully administered to prevent harming the cells. Nanostructure trapping entails
fabricating structures such as retaining walls around each pore using the same etching
techniques as used in fabricating the pores. Vacuum trapping consists of creating a pressure
differential through each pore. In dielectrophoresis, a nonuniform electric field is applied
to the cells which polarizes them and results in their movement. Finally, magnetic tweezers
involve delivering magnetic particles into cells and applying a magnetic field to guide
them. Additional cell trapping methods such as optical tweezers, acoustic tweezers, and
hydrodynamic tweezers exist but to our knowledge have not yet been demonstrated for cell
positioning prior to porous substrate electroporation.

Author Manuscript
Author Manuscript

The geometry and distribution of pores are fundamental in determining how much of the
cell membrane is exposed to the electric field and the electric field strength itself. Longer,
narrower, and fewer pores increase the voltage drop across the pores which thereby increases
the electric field strength within the pores and decreases the electric field strength at the
cell membrane. The electric field strength influences the electrokinetic movement of cargos
within the pores. Pore diameters range from 20–5000 nm with most located in the range of
100–650 nm. Pore lengths vary from 1–60 μm with most falling in the range of 10–30 μm.
Pore densities range from 1E3–1E11 cm−2 with a common range of 4E4–8E8 cm−2. When
not mentioned in the literature, values for pore dimensions and pore density were gathered
from product catalogs, or in the case of pore densities, approximated from other available
dimensions. Porous substrates can be divided into two main categories based on uniformity
of pore distribution: membranes and arrays. These two categories share similar delivery
mechanisms but have significant differences in their fabrication and implementation. Porous
membrane systems have membranes with randomly distributed pores, while porous array
systems are made of etched and photolithographed silicon with uniformly spaced pores.
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The advantage of porous membrane systems is how simple they are to design and
manufacture, which is why they were used for some of the earliest porous substrate
systems[154, 156]. Porous membrane systems primarily utilize track-etched polymer
membranes, which have been used commercially for filtration purposes, although anodic
alumina membranes have also been used[154, 155, 157]. Moreover, track etching is a simpler
process than multiple deep reactive ion etching (DRIE) and photolithographical steps, and
the membranes required for these systems are already commercially available, making
porous membrane systems easier to scale up for medical and industrial applications. In
addition to their availability, porous membranes are much softer and more elastic than
silicon, making them more physiologically relevant than silicon which has a stiffness of
over 100 GPa[184], much higher than the 20 GPa stiffness of cortical bone[185]. Substrate
stiffness has been shown to significantly affect cell behavior through proliferation[186],
differentiation[1], and reprogramming[2].
Despite these advantages of porous membranes with respect to porous array systems, their
simplicity and ease of use have drawbacks due to their stochastic fabrication process.
The construction of these membranes entails ion bombardment of thin polymer sheets,
producing randomly spaced and oriented channels as they pass through the material. After
ion bombardment and subsequent ultraviolet light exposure, the reactivity of the tracks to
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an etchant is increased[187], meaning exposure time to the etchant is used to control the
size of the pores, which are homogenous in size but can be tuned to be tens of nanometers
to several micrometers in diameter. Channels can be created with a smooth and uniform
cross section[188], although significant variation in length can exist from channel to channel,
when channels are angled substantially from perpendicular to the substrate. Variations in
channel length complicate delivery modeling and optimization compared to arrays, which
are more uniformly fabricated. Furthermore, the random distribution of pores can cause
variable delivery between cells. However, variation in the number of exposed pores per cell
may be insignificant when utilizing membranes with a sufficiently high pore density, which
can result in hundreds or even thousands of pores beneath each cell.
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Porous array systems seek to resolve the complications resulting from nonuniform
pores found in track-etched membranes[169, 170]. DRIE and photolithography are used
to create silicon wafers with uniformly spaced and uniformly dimensioned micro- and
nanochannels[189]. Metal-assisted chemical etching (MACE) using nanosphere lithography
has been demonstrated as an alternative to DRIE for creating uniform arrays of
pores[190, 191], but arrays fabricated with MACE have not yet been combined with porous
substrate electroporation. Contrary to porous membrane systems, porous array systems
utilize a single pore beneath each cell, and there are more options for substrate modification
than porous membranes, which can only primarily adjust pore size, pore density, and surface
coating.

Author Manuscript

Porous array systems have drawbacks when compared to porous membrane systems due to
their increased complexity. The fabrication process for porous array systems is much more
difficult, requiring the use of cleanrooms, and different substrates may need to be fabricated
for different cell types. Porous arrays are also more fragile than porous membranes which
limits the number of times they can be reused. Additionally, to take advantage of the uniform
channels, cells must be precisely positioned over each pore, which requires employing cell
trapping methods.
3.3

Cells Used

Author Manuscript

Perhaps the most important data concerning porous substrate systems are the cell types
that have been used with it, including their corresponding viability, efficiency, and dosage
control, because these are the metrics by which all intracellular delivery methods are
evaluated. Viability is the percentage of cells that remain living after delivery, efficiency
is the percentage of original cells containing cargo after delivery, and dosage control is a
measure of how variable the amount of cargo is from cell to cell. These metrics are the
basis of all discussion surrounding the feasibility of any intracellular delivery system, yet
can be very difficult to interpret because they are confounded by many aspects of a system
including cell type, cargo size, electrical parameters, substrate pore size and distribution,
and whether surface coatings were used. Moreover, viability and efficiency are tradeoffs that
must be balanced because the more disruptive a method is, the more cargo will be delivered
(higher efficiency) and the more likely the cell will die (lower viability). Of these three
metrics, viability and efficiency are widely reported across intracellular delivery methods,
whereas discussion of dosage control is limited to highly controllable systems, and indeed
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even a minority of porous substrate systems discuss it[160, 163, 165, 168]. As a result, viability
and efficiency are the two primary metrics discussed here.
Viability is a binary indicator of cell health often measured using a propidium iodide
(PI) and calcein AM live-dead assay or trypan blue exclusion assay. Although viability
is a simple parameter to measure, it neglects to inform whether cellular processes are
functioning at or near predelivery levels in surviving cells. To better understand the harmful
effects elicited by intracellular delivery, Tay and Melosh have proposed more detailed
metrics such as intracellular calcium levels and RNA transcriptomics[192]. Furthermore,
viability measurements are often taken at inconsistent time points after delivery, with some
authors measuring hours afterwards, and others measuring days afterwards.
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The second primary metric, efficiency, encompasses the broad term delivery efficiency,
which is efficiency irrespective of cargo type, and transfection efficiency, which is
strictly defined as the percentage of cells containing delivered nucleic acids. Transfection
efficiency is the focus of this section because it is necessary for many intracellular delivery
applications and is generally a higher standard than delivery efficiency, which can include
smaller proteins and fluorophores. Transfection efficiency can vary significantly depending
on the cargo delivered because nucleic acids such as molecular beacons, oligonucleotides,
and messenger RNA (mRNA) have higher transfection efficiency since they are smaller than
DNA and do not require nuclear localization for their delivery to be observed. Transfection
efficiency reported as a result of genetic editing using CRISPR/Cas9 or alternatives is even
lower because the cargo must not only be delivered to the nucleus but must also successfully
edit the gene of interest. For reference, Cao et al. measured transfection efficiencies of
porous membrane systems using 4 different cell lines and reported efficiencies of 75–80%
for mRNA, 40–80% for plasmid DNA, and approximately 25% for CRISPR/Cas9 genetic
editing[151].
Transfection efficiency is known to be heavily dependent on the type of cell used, with
immortalized cells being the easiest to transfect, and cells such as primary and stem cells
being known as “hard to transfect” cell types. Although the majority of studies with porous
substrate systems have been performed on immortal cells, their effectiveness has also been
demonstrated on primary and stem cells, including particularly difficult to transfect neurons
[153] and cardiomyocytes[161]. Furthermore, despite their aptitude for transfecting adherent
cells, porous substrate systems have demonstrated the ability to transfect multiple suspended
cell lines as well as primary leukocytes using centrifugation or cell trapping.
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Table 2 contains all cell types used with porous substrate electroporation and relevant
data such as cell culture surface coatings, viability, and transfection efficiency. Cell culture
coatings are predominantly used to increase cellular adhesion around the pores, except
for polyethylene glycol (PEG) -silane which was used increase cell detachment between
experiments[163]. Values for viability and transfection efficiency were taken from the same
experimental conditions since the 2 parameters are tradeoffs and when multiple values were
provided, the highest combined values were included. If percentages were not explicitly
stated, values were taken from bar graphs and rounded down to the nearest 5%. If multiple
studies used a cell line, the highest values were included and the study was cited. For
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some cell lines, population-wide data was not reported, but transfection was shown through
fluorescent images and graphs of fluorescent intensity. BEAS-2B and HL-60 are the only
cell lines listed that were not transfected. BEAS-2B was used to understand cell trapping
and fluorophores were delivered to HL-60 but not nucleic acids, as such, the transfection
efficiency listed for HL-60 is delivery efficiency and is noted in the table.
3.4

Cargo Properties
A wide variety of cargos have been delivered or extracted using porous substrate
electroporation systems (Table 3). These cargos range from tiny ions, small molecules,
and fluorophores, to massive nucleic acids. Although studies have primarily focused on
delivery of these cargos, extraction of intracellular molecules using porous substrates has
also been demonstrated[152]. Cargo parameters influencing successful intracellular delivery
or extraction include molecular charge, size, and the composition of the delivery solution.
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Charge plays a significant role in cargo delivery because the localized electroporation
employed by porous substrates is electrophoretically dominated. Therefore, the charge of
the cargo must be known to use proper electrode polarity for delivery. When delivering
negatively charged molecules, the anode must be placed on the cell culture side of the
porous substrate, and the cathode must be placed on the side of the porous substrate
containing the cargo. Likewise, the polarity of the electrodes must be reversed when
delivering positive cargo. An additional consideration is that electrophoresis occurs in both
directions during electroporation. While one polarity of molecules is being delivered into the
cells, molecules of the other polarity are extracted from the cells.
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The role of cargo size in intracellular delivery using porous substrates is more complex.
Although pore formation has not been observed in porous substrate electroporation,
Mukherjee et al.[152] presents a computational model which predicts higher voltages
increase pore diameter up to a critical voltage, after which the pores collapse and additional
voltage generates smaller pores but in a greater number. The theoretical size of these high
voltage pores is 3 nm in radius, meaning molecules smaller than these pores are delivered
in greater quantities as voltage is increased due to an increase in the electrophoretic force
(Figure 3E). Conversely, molecules greater than 3 nm in radius are maximally delivered at
voltages just below the critical voltage. The results of this simulation were corroborated with
the delivery of different sized molecules in the same paper, and are supported by data from
other researchers in this field[181, 193]. For comparison, the size and mass of each cargo was
listed when known. Nucleic acids are primarily measured in the number of base pairs, from
which mass estimates were calculated using formulas presented by Thermo Fisher Scientific.
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Additional cargo factors governing delivery are solvent formulation and cargo concentration.
The results from cargo delivery are associated with the concentration of cargo within the
delivered solution, yet many of these cargos are cytotoxic when delivered at too high
of concentration. Furthermore, solvents used for delivery must be electrically conductive
and biocompatible, with phosphate buffered saline (PBS) and Dulbecco’s modified Eagle’s
medium (DMEM) commonly used. The delivery solution should also contain a pH buffering
system to minimize the toxic pH change caused by electrolysis[136]. Furthermore, diluting
the delivery molecules in a hypo-osmolar buffer increases membrane tension through
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intracellular swelling, thereby reducing the voltage required for permeabilization[194], and
perhaps more importantly, increasing the radii of pores produced at high voltage[152].
3.5

Electroporation Waveforms
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Researchers have been optimizing waveforms for electroporation for decades, with an
emphasis placed on square and exponential decay waveforms. Bipolar square waveforms
have been shown to be more efficient than unipolar exponential decay and square waveforms
in bulk electroporation because the membrane is permeabilized on both sides of the cell[195].
However, unipolar square pulses are favorable for porous substrate delivery because the
cargo is located on one side of the cell and generally unipolar, thus unidirectional
electrophoresis is thought to result in greater delivery, but to our knowledge this has not
been demonstrated. As such, most studies on porous substrate electroporation have utilized
unipolar square pulses, although a few earlier studies were performed with exponentially
decaying waveforms[157, 167]. To the best of our knowledge, no studies have been performed
showing the effects of different waveforms specifically applied to porous substrate systems,
only the effects of varying voltage, frequency, and number of pulses of unipolar square
waveforms.
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Comparing waveforms between papers is valuable for understanding which parameters are
often used, both as a starting point for new researchers and to point out conditions where
data is lacking. Unfortunately, this comparison proved difficult due to many waveforms
being incompletely explained, and listed parameters often used different terminology from
author to author. For this reason, we created a standardized terminology for describing
unipolar waveforms (Figure 3F). Using this framework, we fit the various parameters from
each paper into Table 4. Pulses were assumed to be square and single level (low voltage
was assumed to be 0) unless otherwise noted. The number of trains was assumed to be 1
and there was assumed to be no train interval unless otherwise noted. Low voltage time
was calculated as the difference between the inverse of the frequency and the pulse duration
(high voltage time). Where applicable, the cargo size for the applied waveform was listed,
reflecting the differences in waveform optimization mentioned in the cargo section for small
and large cargo. In accordance with the findings by Mukherjee et al.[152], small cargos are
strictly defined as molecules containing radii less than 3 nm, although due to the lack of
information for many molecules, as well as the fact that nucleic acids are narrow but can be
extraordinarily long, small cargos are defined in this paper as having radii less than 3 nm
and a mass less than 50 kDa. This definition includes ions, small molecules, fluorophores,
oligonucleotides, micro RNA, and molecular beacons, while proteins, messenger RNA, and
DNA are classified as large cargos. It should be noted that this distinction has not been
extensively supported and is provided for comparison purposes only.
Commonalities between chosen waveforms can be seen in Table 4. Applied voltages range
from 1 to 250 V, with common values being 15–140 V. Applied voltage depends on the
resistance of the system and therefore varies depending on the substrates chosen. Low
voltage is almost always 0 V, with the notable exception of Kang et al., who used bilevel
pulses to deliver large cargo[153]. The high voltage duration ranges from 0.2–500 ms, but
common values are 5–30 ms. Low voltage duration varies from 2.5–1000 ms, and low
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voltage duration is generally much longer than the high voltage duration, although rarely the
durations are equivalent. Pulse frequencies have been reported from 1–200 Hz. The number
of pulses applied per train range from 1–2400 pulses, while the number of trains is generally
1 and no more than 10. When multiple trains were used, train intervals were 500–1000 ms.
Overall, there is a significant amount of data regarding waveform specifications that has not
been published, making it difficult to draw conclusions. Furthermore, there are significant
variations between the many applied waveforms, signifying the pressing need for further
waveform optimization with respect to porous substrate systems.

4.

Conclusion and Outlook
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This review examined intracellular delivery methods from the perspectives of throughput
and control. Currently, viral transfection, lipid transfection and bulk electroporation
represent the most widely used high throughput methods for gene delivery. Flow-through
microfluidic based mechanoporation and electroporation possess the highest throughput
capacity of any existing methods and eliminate some of the drawbacks of viral transfection
and bulk electroporation, while automated probe-based methods provide subcellular control
but are lacking in throughput potential. Engineered substrate methods offer a balance
by maintaining high throughput capacity while further improving control aspects such
as delivery efficiency, cell viability and dosage control over the dominant methods used
today. Porous substrate electroporation is a particularly promising and under investigated
engineered substrate method which we reviewed in detail.
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Within porous substrate electroporation specifically, there are a few potential areas where
significant improvement can be made in the coming years. First, control of cell-ECM
and basal membrane tension may facilitate larger pore formation with a tight seal
between the substrate and the cell membrane, the translocation of large plasmids with
complex shapes, and the delivery of controlled amounts of cargos. Second, the choice of
porous substrate materials, the selection of micro/nanochannel dimensions, and the design
of electrical waveforms all play a vital role in regulating the generation of electrical
potential both at the membrane and at the micro/nanochannels, and in determining the
transport of cargo molecules across the micro/nanochannels in the context of complicated
electrokinetic landscapes. In addition, for porous substrate arrays, new techniques for
patterning cells are prerequisite to facilitate high throughput requirements. Lastly, porous
substrate electroporation has predominantly been used in proof of concept studies, therefore
studies should begin investigating more complex applications such as temporal sampling of
molecules of interest for real-time monitoring in live cells; batch production and extraction
of industrial proteins; and transdifferentiation and iPSC reprogramming.
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Beyond porous substrate-based electroporation, automated probe-based methods and
flow-through microfluidic methods are well suited to other applications. Flow-through
microfluidics are unparalleled for applications containing non-adherent cells such as
analysis or modification of blood cells. Meanwhile, automated-probe based methods are
uniquely capable for studying fundamental biological mechanisms in adherent cells across
large populations. However, challenges remain with intracellular delivery in general. First,
to fulfill challenging applications such as high throughput, uniform iPSC reprogramming,
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intracellular delivery systems must be able to both process millions of cells and be viewed
in the context of current state-of-the-art single cell analysis, in which the heterogeneity
of individual cells is examined. In this regard, there is a need for systems that deliver
with similar control to single-cell delivery platforms while maintaining high throughput.
In addition, most intracellular delivery methods outside of probe-based methods have been
unable to demonstrate rapid delivery of DNA to the nucleus, often requiring many hours
for translation to be detected. Lastly, innovative biological assays are needed to provide
more accurate metrics for examining cell health after delivery for precise quantification of
unintended side effects.
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Figure 1. Throughput and Control Classification of In Vitro/Ex Vivo Intracellular Delivery.

Tree structure of the three main categories of in vitro/ex vivo intracellular delivery, their
subcategories, and specific methods. High throughput, low control methods are shown in
yellow; low throughput, high control methods are shown in blue; and high throughput, high
control methods are shown in green.
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Figure 2. High Throughput, High Control Methods.

Simplified depictions of high throughput, high control methods next to actual images of
each method. The electroporation polarities shown are for delivering negative cargos. A.
Automated probe-based injection. i. automated injection of zebrafish embryos [87] ii-iii.
Different magnifications of an atomic force microscope tip with attached carbon nanotube
needle (scale bar = 8 μm and 500 nm, respectively) [48] iv. cell held using a vacuum during
injection [50] v-vi. real and simulated deformation during injection (needle diameter = 10
μm) [77] B. Automated probe-based electroporation. i-ii. image processing showing nuclear

Small. Author manuscript; available in PMC 2022 January 05.

Brooks et al.

Page 31

Author Manuscript
Author Manuscript

site in green and cytoplasmic site in red, followed by automated electrode positioning
[90] iii. nanofountain probe electroporation (cell size ~ 10–20 μm) [58] iv. An improved
version of nanofountain probe using silicon nitride for a soft touch (scale bar = 30 μm)
[13]. C. Flow-through microfluidic electroporation. i. vortex microfluidic electroporation
(scale bar ~ 720 μm) [97] ii. microfluidic electroporation device (scale bar = 6 mm) [96] iii.
sawtooth microfluidic electroporation (scale bar = 40 μm) [95] D. Flow-through microfluidic
mechanoporation, including cell squeezing and hydroporation. i. microfluidic constrictions
for cell squeezing (scale bar ~ 250 μm) [92] ii-iii. microfluidic constrictions showing single
and double deformation, respectively (scale bar = 10 μm) [103] iv. hydrodynamic shearing
in hydroporation [105] v. spiral hydroporation [104] E. Nanostructures. i. nanoneedles (scale
bar = 2 μm) [110] ii. cell adherent to nanostraws with false color added (scale bar = 10
μm) [121] iii. primary T cells on nanowires with false color added (scale bar = 10 μm) [115]
iv. internalized nanowires with the cytoplasm dyed green and the cell membrane dyed red
(scale bar = 10 μm) [111] v. neurons adherent to nanowires with false color added (scale
bar = 10 μm) [114] vi-vii. silicon nanotubes used for biomolecular cargo delivery (scale bars
= 1 um and 10 μm, respectively)[118] G. Patterned electrode electroporation. i. electrode
electroporation device with multiple inputs [149] ii. clover electrodes (scale bar = 5 mm) [143]
iii. interdigited electrodes [136] iv. 3D interdigited electrodes (scale bar = 800 μm) [141] H.
Porous substrate electroporation. i. anodic alumina membrane (scale bar = 1 μm) [155] ii.
polycarbonate membrane microfluidic device (scale bar = 12 mm) [153] iii. porous array with
nanostructure trapping mechanism (scale bar = 200 μm) [161] iv. DAPI stain showing cell
seating on porous array (scale bar = 100 μm) [164]. Permission is needed.
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Figure 3. Porous Substrate Electroporation.

A. The 4 cell trapping mechanisms that have been demonstrated. From left: nanostructure,
vacuum, magnetic tweezers, and dielectrophoresis. B. A cell adhered to a porous
substrate and undergoing electroporation. Equivalent circuit elements are shown near their
corresponding features. C. A magnified view of the cell-channel interface showing the
voltage drop along the channel. D. The transition from hydrophobic pores to hydrophilic
pores that occurs during electroporation. E. A further magnified view of the cell membrane
showing the 3 nm radii pores that form at high voltage as predicted by Mukherjee et
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al. Under the current electrode configuration, electrophoresis extracts positive cargos and
delivers negative cargos. From left, the cargos propidium iodide (PI), linear DNA, and
bovine serum albumin (BSA) are shown to scale. F. An electroporation waveform consisting
of two trains, each with three unipolar square bilevel pulses. The parameters high voltage
(HV), low voltage (LV), high voltage duration (t1), low voltage duration (t2), and train
interval (t3) are shown. Single level and exponential decay pulses are also shown.
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Design Parameters of Porous Substrate Systems
Type

Substrate Material

Electrode Material

Cell Trapping
Mechanism

Titanium
Track-Etched
Polycarbonate

Track-Etched PET

Pore
Density
(cm−2)

100

20

2E7

[151]

Ref.

ITO-Coated Glass

200

25

5E8

U: Silver/Silver
Chloride, L: GoldCoated Glass

600 2000

24 23

4E7 3E6

[153]

Silver

Vacuum

U: Track-Etched PET,
L: Anodic Alumina

Author Manuscript

Platinum-Coated
Glass

Array

Pore
Length
(μm)

[152, 158]

Membrane

Anodic Alumina

Pore
Diameter
(nm)

U: 3000 L:
400

[156]

U: 3000 L:
200

U: 10 L: 60

U: 8.5E5
L: 8.0E8

[157]

20

45

1E11

[154]

Author Manuscript

Gold-Coated Upper
and Lower Membrane
Surfaces

Vacuum

100–200

60

U: Copper, L: GoldCoated Glass

Vacuum

650

20

U: Neon Transfection
System Electrode, L:
Gold-Coated Glass

Nanostructures

400

10

U: ITO-Coated Glass,
L: Gold-Coated Glass

*

300

10

4E4

[162]

U: Platinum, L: GoldCoated Glass

Magnetic
Tweezers or
Vacuum

5000 5000

30 30

1E3 4E4

[163]

Dielectrophoresis

650

Dielectrophoresis

300

10

4E4

[165]

500

20–25

4E4

[166]

Vacuum (L)

1000 (U)
2500–3500
(L)

10 (U) 12–
13 (L)

1.6E6 (U)
2.5E5 (L)

[167]

Vacuum

2000 5000

1

1.8E4

[168]

DRIE and photolithographed silicon

U: ITO-Coated Glass,
L: Gold-Coated Glass

Gold-Coated Glass

[155]

4E6

[160]

[161]

[164]

U and L denote upper and lower, respectively, in instances where there is a difference between electrodes or when porous substrates are used both
above and below.

*

Optical tweezers were used in this study but are only mentioned for positioning cells in the 2D channels, not for positioning on the porous
substrates.
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Cell Types Used in Porous Substrate Systems
Type

Organism

Cell Line

Description

Surface Coating

A375

Melanoma

BEAS-2B

Transformed
Bronchial Epithelial

Gelatin, BSA,
PEG

HEK293

Embryonic Kidney

Poly-L-Lysine or
Fibronectin

HeLa

Cervical Epithelial

Poly-L-Lysine [151]
or Fibronectin

Viability

Transfection
Efficiency

Ref.

>90%

>90%

[168]

[168]

>90%

80%

[151]

>95% [151]

>80% [151]

[151, 153, 154, 159]

>90%

65%*

[155]

50% [153]

[152, 153, 159]

75% [151]

[151, 163]

[151, 154]

HL-60

Promyeloblast,
Suspended

HT1080

Connective Tissue

Fibronectin [152]

Jurkat

T Lymphocyte,
Suspended

Poly-L-Lysine or
Fibronectin [151],
PEG-Silane [163]

>95% [151]

KG1a

Promyeloblast,
Suspended

PEG-Silane

96%

K562

Lymphoblast,
Suspended

PEG-Silane [163]

92% [163]

83.4% [163]

[163, 164]

MDA-MB231

Mammary Epithelial

Fibronectin

>99% [152]

70% [152]

[152, 158]

NK-92

Natural Killer,
Suspended

90%

74%

[165]

Mouse

NIH3T3

Embryonic Fibroblast

>95% [151]

75% [151]

[151, 156]

Rat

H9C2

Embryonic Cardiomyoblast

HCF-a

Myofibroblast

None

Leukocyte,
Suspended

None

Cardiomyocyte

86%

86%

[161]

None

Embryonic Fibroblast

>90% [161]

>90% [161]

[160, 161]

None

Neuron

GBM157

Glioma Stem

GBM528

Glioma Stem

CCE

Embryonic Stem

Human

Author Manuscript

Immortal

Author Manuscript

Human
Primary
Mouse

Poly-L-Lysine or
Fibronectin [151]

[163]

[160, 165, 166]

95.6%

90.5%

[163]

PEG-Silane

Poly-D-Lysine

[168]

>90%

[153]

>70%

[162]

Human
Stem
Mouse

[162]

Gelatin [167]

>85% [167]

*

Delivery efficiency, not transfection efficiency. No nucleic acids were delivered in this study.
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Large

Small

Plasmid DNA

Messenger RNA

Protein

Molecular Beacon

Micro RNA

Oligonucleotide

Fluorophore

54.2

tdTomato

3.3 kb

~2000
~3500
~4000
~2400

GFP
gWiz GFP
gWiz SEAP
mCherry

4 kb

6.6 kb

5.8 kb

9 kb

711 nt

Varies

Varies

3 nm rh

45 nt

CS1-CAR

~228

Varies

PTPs

mCherry mRNA

98

Varies

Cas9 RNP
mCherry STIM1

66.5

13.9

Alexa Fluor 488 BSA

GATA2

FAM-VIM

-

-

-

-

-

-

-

Varies

+

-

-

-

-

-

-

-

CD133

21–23 nt

18 nt

-

+

-

+

Charge

-

~6.9–7.5

5.684

0.6 nm rh

0.49 rh

0.125 nm rh

Size

CD44

miR-29

FAM-ODN

Anti-miR-363

0.668

0.457

Lucifer Yellow CH
PI

0.194

0.182

Dacarbazine

Ion

Temozolomide

0.059

Co2+

Small Molecule Drug

Mass (kDa)

Molecule

Type

[162]

20 μg/mL

[152]

[156, 157, 167]

High Glucose DMEM[157, 167]

5[167] −100[157] μg/mL

[151, 153, 159]

[165]

[151]

[152]

[158]

[151]

[151]

[152, 158]

[163, 164]

[168]

[162]

[162]

[161]

[160, 163, 165, 166]

[156]

DMEM [153]

Extracted

Extracted

[158]

Hypo-osmolar buffer [152],
Iso-osmolar buffer [152], PBS

PBS

PBS

PBS

[152, 153, 159, 160, 163, 165, 167]

[154, 155]

[162]

[168]

[152]

Ref.

<50 μg/mL

0.2[151] – 1000[153] μg/mL

0.1 μg/mL

Extracted

Extracted

10 μM

2500 μg/mL

0.005–5 μM

PBS[153], High Glucose
DMEM[167]

DMEM[154], PBS[155]

1000[155] −2000 μg/mL[154]
2[153]−20[152] μg/mL, 100 μM[167]

PBS

PBS

Solvent

5 μM

10 μM

Concentration
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Linear DNA

~2900
~2100

pDsRed-C1
pmaxGFP
~29500

~7900

OSKM pCAG

YOYO-1-λ

>5500

NF2 CRISPR/ Cas9 KO

Author Manuscript
Mass (kDa)

48.5 kb

3.5 kb

4.7 kb

13 kb

>9 kb

Size

-

-

-

-

-

Charge

0.03 μg/mL

Tris-EDTA buffer

[156]

[160, 161, 165, 167]

5 μg/mL[167]

[160]

[168]

Ref.

[154]

High Glucose DMEM[167]

Solvent

100 μg/mL

Concentration

Author Manuscript
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Author Manuscript
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Electroporation Waveforms Applied to Porous Substrate Systems

Pulse Shape

Low
Voltage
(V)

High
Voltage
Duration
(ms)

Low
Voltage
Duration
(ms)

Pulse
Frequency
(Hz)

Pulses/
Train

Number
of Trains

Train
Interval
(ms)

Ref.

0

10

None

None

1

1

None

[164]

1–4

0

20

1000

1

10

1

None

[155]

10

0

10

5

1

None

[163]

3–15

0

20

1

1

None

[154]

15

0

0.5

1–3

1

None

[152]

20

0

2.5

2.5

200

200

2

1000

[153]

10–25

0

20

None

None

1

1

None

[168]

15–140

0

5–30

1000

1

2–5

1

None

[160]

15–140

0

5–30

1000

1

5

1

None

[165]

15–140

0

5–30

1

None

[166]

50–200

0

5–20

1–10

1

None

[161]

200–250

0

5–20

2–5

1

None

[162]

*

0

500

5

1

None

[156]

4

0

50

10

1

None

[163]

6

0

20

None

None

1

1

None

[154]

10–50

0

5

45

20

100–
500

1

None

[152]

15–90

0

0.2

49.8

20

400–
2400

1

None

[151]

100

0

20

None

None

1

1

None

[165]

200

0

10

1

None

[161]

80–100

10

0.25

3

200

50

8

500

[153]

30

10

0.5

2.5

0.5–10

200–
400

1

None

[158]

Large

*

0

None

None

1

1

None

[157]

Both

*

0

None

None

1

1

None

[167]

Cargo
Size

High
Voltage
(V)

None

None

Small

Author Manuscript

Single Level
Square

Large

Author Manuscript

Bilevel Square

Exponential
Decay

500

1

Large

*

Values are provided for the electric field but not the voltage.
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